The population of older adults living with dementia is expected to swell to nearly 14 million by 2050 and is estimated to cost the US economy more than 500 billion each year. In the absence of a cure for Alzheimer's disease, the primary cause of dementia, there's interest in understanding modifiable risk factors. In theory, getting a handle on the modifiable risk factors for dementia, would enable public health efforts to reduce cognitive decline in dementia at the population level. We've come a long way in understanding the risk factors for Alzheimer's disease and other related dementias. However, there's still work to be done. In this episode, we'll speak with Dr. Josh Ehrlich, a researcher at the University of Michigan, who has examined vision impairment as a risk factor for dementia.

The fast-acting pill, paired with psychosocial treatment, offers a comprehensive treatment plan, but price concerns remain. Visit Health Lab to read the full story.

According to an estimate published in 2015, the global prevalence of dementia was projected to nearly triple between 2015 and 2050, growing from 46 million to over 130 million people globally. And of that worldwide share, 70% of those with dementia will be in low- and middle-income countries. Tackling and ideally preventing dementia requires a global perspective. In this episode, Matt & Donovan speak with Dr. Lindsay Kobayashi, a faculty member in the Department of Epidemiology at the University of Michigan School of Public Health whose research focuses on the social epidemiology of aging from a global perspective. Dr. Kobayashi introduces us to a whole new world of data available to help researchers tackle dementia as a global challenge.

Evidence can help inform fertility care for transgender and gender diverse people who wish to become parents. Visit Health Lab to read the full story

Over thirty percent of individuals living with dementia living in the US each year die either of or with dementia – and almost half of those enrolled in hospice have dementia. As with so many other types of healthcare, there are disparities in both who enrolls in hospice as well as the type of care these individuals receive after enrollment. In this episode, Matt & Donovan talk with Dr. Lauren Hunt from UCSF, an expert in hospice care for persons living with dementia, about dementia at the end of life.

A study explores how to better provide resources to sexual partners of those with STIs. Visit Health Lab to read the full story

Extreme weather and weather-related disasters are becoming more and more common. Unfortunately, disaster related disruptions in healthcare tend to affect the most vulnerable of populations – including older adults living with cognitive impairment. In this episode, Matt & Donovan speak with University of Michigan faculty member, Sue Anne Bell, about how healthcare disruption due to a disaster can affect the population of older adults living with dementia.

For kids with epilepsy, seizures can strike at any time. Here’s what you can do to help.

In this episode of Minding Memory, we dive into the newest FDA-approved drug to treat Alzheimer’s – Lecanemab – with Ohio State University stroke neurologist Jim Burke. Dr. Burke discusses the benefits and drawbacks of the new Alzheimer’s drug and also the paradigm shift of how people (clinicians, patients, and the general population) are thinking about these news Alzheimer’s medications.

It’s not a booster, it’s a new vaccine just in time for respiratory infection season.

In this episode, Donovan & Matt talk with health services researcher Betsy White from Brown University about a unique new resource for researchers called the Long-Term Data Cooperative, a provider-led data sharing collaboratory that puts together nursing home EHR data from EHR vendors that can be linked to Medicare claims. This powerful tool is made available to researchers through an online application process.

Oral care is important, and your prenatal care should involve a trip to the dentist. Visit Health Lab to read the full story.

The collection of close to 2,000 samples provides an unbiased view of canine genetics.

Researchers look into a drug called proxalutamide as a potential therapeutic for the coronavirus.

A study seeks to determine post surgery outcomes from patients.